A joint study has shown that the highest cost in rheumatoid arthritis results from patients having to leave the workforce early due to the disease ... (more)

Patients with rheumatoid arthritis (RA), the most common chronic inflammatory arthritis, are twice as likely as other individuals to experience depression ... (more)

Individuals with the inflammatory bowel disease ulcerative colitis are at increased risk of developing colon cancer ... (more)

HUMIRA® is approved for reducing the signs and symptoms, inducing major clinical response ... (more)

For nearly two decades, BioPlus CEO Dr. Stephen Vogt has remained focused on measurably improving pharmaceutical patient care ... (more)

BioPlus® Specialty Pharmacy announced today that it is prepared to release results of its ongoing Therapy Management programs ... (more)

We are extremely proud to, once again, be accredited by CHAP (Community Health Accreditation Program) ... (more)

BioPlus® is extremely proud to be selected as the preferred provider of specialty medications for MaineCare members ... (more)

Widely used anemia drugs sold by Amgen and Johnson & Johnson raise the risk of death among cancer patients by about 10 percent ... (more)

A drug made by Genentech received federal approval on Friday to treat breast cancer, a decision that could represent a major shift in standards for assessing the effectiveness of cancer medicines ... (more)

New findings show that a specialized virus with the ability to reproduce its tumor-killing genes can selectively target tumors in the brains of mice and eliminate them ... (more)

Individuals with the inflammatory bowel disease ulcerative colitis are at increased risk of developing colon cancer ... (more)

It sounds too good to be true ... a little inexpensive pill that could block the development of some cancers, strengthen bones, prevent multiple sclerosis and alleviate winter depression ... (more)

A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia ... (more)

Researchers at UCLA's Jonsson Cancer Center have discovered biomarkers that predict which patients with advanced non-small cell lung cancer will respond to a combination treatment ... (more)

An innovative research approach has identified a previously unsuspected protein as a key player in the resistance to particular forms of breast cancer therapy ... (more)

An international research study has thrown into question the current method of treating Crohn's disease ... (more)

An international research study has thrown into question the current method of treating Crohn's disease ... (more)

After following participants for one year, a large Japanese study concludes that treating Hepatitis C aggressively reduces the occurrence of non-Hodgkin's lymphoma ... (more)

A new study from Bulgaria proves that Hepatitis C infection is not only a liver disease, but affects many different parts of the body ... (more)

As the pioneers of specialty pharmacy, BioPlus strives to make pharmaceutical care accessible to everyone ... (more)

Roche today announced that the company will conduct the largest study to date comparing hepatitis C treatment response rates... (more)

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases... (more)

Researchers in Australia have discovered an antibody that has helped some people develop immunity against hepatitis C ... (more)

New results show treating early with Pegasys® combination therapy significantly increases chance of achieving a cure ... (more)

Given that standard hepatitis C therapy with pegylated interferon plus ribavirin produces a sustained virological response ... (more)

A drug therapy currently used to treat non-Hodgkin's lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical trial ... (more)

By comparing the DNA of patients with multiple sclerosis whose symptoms are reduced by interferon beta therapy ... (more)

Patients with severe psoriasis appear to have an increased risk of death compared with patients without the skin condition, according to a new article ... (more)

Abbott announced today it has received FDA approval to market HUMIRA® (adalimumab) as a treatment for adult patients with moderate to severe chronic plaque psoriasis ... (more)

Are biotechnology companies reaching the limits of how much they can charge for their drugs? ... (more)